Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Vaccine syringe and a bottle marked malaria vaccine

Sanaria Inc. has been developing vaccines against Plasmodium falciparum (Pf) since 2003.  Pf is the deadliest of the five types of parasites causing malaria in humans.  It was responsible for 627,000 deaths in 2020, the most deaths since 2012, mostly in children and pregnant women in sub-Saharan Africa.  Sanaria’s vaccines are composed of the infectious form of the Pf parasite, called the sporozoite (SPZ). The PfSPZ are attenuated by radiation, co-administration of an antimalarial drug, or gene-knockout, so that they can be administered safely to people.  The highly purified product has no adjuvant and injections have been safe and well tolerated in multiple trials.

The Mali trial is being performed by the Malaria Research and Training Center (MRTC), University of Bamako, in collaboration with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the US National Institute of Allergy and Infectious Diseases (NIAID).  Dr. Issaka Sagara is the lead investigator from MRTC, and Dr. David Cook from LMIV. 

The Indonesia trial is being performed as a collaboration between the Indonesian Army, the Eijkman Institute, the University of Indonesia School of Medicine, and the University of Oxford. Dr. Erni Nelwan, from the University of Indonesia, serves as lead investigator. The performing clinical team, led by Dr. Krisin Chand, is from the Eijkman-Oxford Clinical Research Unit (EOCRU), which is currently onsite working with Army medical officers to immunize the soldiers prior to deployment.

Read the full story on the Centre for Tropical Medicine & Global Health website

Similar stories

Misophonia: nearly one in five UK adults have the condition causing extreme reactions to certain sounds

Many of us have sounds that we find to be annoying. But for some people, certain sounds actually trigger extreme reactions.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at the Nuffield Department of Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine.

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Athena Swan Gold Award success for Nuffield Department of Primary Care Health Sciences

The award reflects the Department’s commitment to representation, progression and success for all. It acknowledges the innovative policies and practices developed across the department and the detailed action plans for improvement.

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.